Resistance to BRAF inhibitors: unraveling mechanisms and future treatment options
about
Other targeted drugs in melanomaIdentification of a Novel Family of BRAF V600E InhibitorsChemically Linked Vemurafenib Inhibitors Promote an Inactive BRAFV600E ConformationDifferential inhibition of ex-vivo tumor kinase activity by vemurafenib in BRAF(V600E) and BRAF wild-type metastatic malignant melanomaPerturbation biology: inferring signaling networks in cellular systemsRegistered Report: COT drives resistance to RAF inhibition through MAP kinase pathway reactivationIt's about time: lessons for solid tumors from chronic myelogenous leukemia therapyThrombospondin 1 promotes an aggressive phenotype through epithelial-to-mesenchymal transition in human melanomaDriver mutations in melanoma: lessons learned from bench-to-bedside studiesTargeting multiple key signaling pathways in melanoma using leelamine.Nanolipolee-007, a novel nanoparticle-based drug containing leelamine for the treatment of melanoma.BRAF Inhibition Stimulates Melanoma-Associated Macrophages to Drive Tumor Growth3'-Deoxy-3'-[18F]-Fluorothymidine PET imaging reflects PI3K-mTOR-mediated pro-survival response to targeted therapy in colorectal cancer.Intravital imaging reveals how BRAF inhibition generates drug-tolerant microenvironments with high integrin β1/FAK signaling.Characterization of the Methylthioadenosine Phosphorylase Polymorphism rs7023954 - Incidence and Effects on Enzymatic Function in Malignant MelanomaMEK genomics in development and diseaseFibroblast-derived neuregulin 1 promotes compensatory ErbB3 receptor signaling in mutant BRAF melanomaAberrant expression of COT is related to recurrence of papillary thyroid cancer.A novel 7-bromoindirubin with potent anticancer activity suppresses survival of human melanoma cells associated with inhibition of STAT3 and Akt signalingSimultaneous targeting of COX-2 and AKT using selenocoxib-1-GSH to inhibit melanomaBRAF V600 mutations in Langerhans cell histiocytosis with a simple and unique assayEvaluation of (68)Ga- and (177)Lu-DOTA-PEG4-LLP2A for VLA-4-Targeted PET Imaging and Treatment of Metastatic Melanoma.Cytokines can counteract the inhibitory effect of MEK-i on NK-cell function.Dependence On Glycolysis Sensitizes BRAF-mutated Melanomas For Increased Response To Targeted BRAF Inhibition.Narrowing the knowledge gaps for melanomaIntratumoral heterogeneity as a therapy resistance mechanism: role of melanoma subpopulations.Heat-shock proteins-based immunotherapy for advanced melanoma in the era of target therapies and immunomodulating agents.Current management of advanced melanoma: a transformed landscape.One Hippo and many masters: differential regulation of the Hippo pathway in cancer.BRAF inhibitors: experience in thyroid cancer and general review of toxicity.Stamping out RAF and MEK1/2 to inhibit the ERK1/2 pathway: an emerging threat to anticancer therapy.PTEN regulates IGF-1R-mediated therapy resistance in melanoma.Targeting ER stress-induced autophagy overcomes BRAF inhibitor resistance in melanoma.Targeting protein kinase-b3 (akt3) signaling in melanoma.Busting robustness: using cancer's greatest strength to our advantage.A long-term survivor with esophageal melanoma and pulmonary metastasis after single-stage esophagectomy and lobectomy: Case report and literature review.Therapy's Shadow: A Short History of the Study of Resistance to Cancer Chemotherapy.Non-V600 BRAF mutations recurrently found in lung cancer predict sensitivity to the combination of Trametinib and Dabrafenib.PET imaging of very late antigen-4 in melanoma: comparison of 68Ga- and 64Cu-labeled NODAGA and CB-TE1A1P-LLP2A conjugates.Enhanced response of melanoma cells to MEK inhibitors following unbiased IGF-1R down-regulation.
P2860
Q26775594-93DEF10B-BCEF-4EDF-B917-BC574C6D3DEDQ27678754-19134873-5F6E-4FAF-950F-43002ECC7A71Q27727954-12B29AAB-07A3-4062-84A9-B00D60269DA3Q28536351-E183F0DE-F74F-4CC8-A225-9C10B69518A6Q28537769-F68BE2FC-03FF-4769-8C33-A1D2432DB002Q28601717-D42D1E66-EE1D-4A97-BD09-57A3BECB5A97Q33936071-8F22FA7C-B47B-4ADE-9F51-1EE0FB7B36B0Q34221697-CC600270-3A57-4386-AE8C-07343B27519AQ34639532-898CCCB2-4CB6-489B-A61D-053F1E79DBF8Q35136450-7F01E744-B733-4AFB-AA3A-2C88C628D45EQ35225907-D5325D94-35C9-46BC-9333-7C5B7ECE91B4Q35251663-2B7886A1-5BAC-49A2-A18D-30E71AD707F4Q35271098-A58D313F-53E6-447F-AD81-BFC1C2A07AEEQ35474544-F6115089-9757-4958-A523-1275FAEE612FQ36091672-63B76B10-33B6-4406-B448-C89CDB9FFCA9Q36099005-1AA08EC6-F402-4E9A-B30E-7BC1D1075DFCQ36115818-5C8448B9-5D19-49DA-B618-45F3E863AF8BQ36152396-4C0CD0A8-2614-44C7-8F1D-54B652E9FB2DQ36384334-4F9F4050-0DC7-421B-B4E8-E96B5CEDAE05Q36536476-D6928B10-05E9-466B-B606-6B38C79ADB2DQ36815539-B784EB08-2AB7-45AC-8587-8A32ECFB7E00Q37515861-B6013488-8144-4665-8668-E2D31DDB5D49Q37641527-B615D9BA-7433-4AA9-AADC-AA1D9F787C21Q37644414-FF78EAB5-76D4-4324-B45B-FA4F4D47562EQ37984547-D271F06E-7DF7-4165-AF45-5438A08CA25DQ38041729-7A5EDF93-E7AA-4264-BEF2-32B4A3F544CFQ38199545-0C782F55-AFF9-4634-BF3A-C9F7F0DE44AEQ38212935-DC27B4EA-7413-4141-A66B-64E4C23F8900Q38238612-B873E26D-6B7D-4BD7-B94F-6FF9B9818AC7Q38281838-D64B8E95-A5BC-402A-A9E8-309EE1C07D1CQ38585847-B234FA2D-5B54-4D6C-9FEE-A1EE1DBD880DQ38859960-CD3D0D35-C384-43A4-954B-CB81CADBAD25Q39020884-2D91337A-A6ED-425D-81C3-402DAF8A103DQ39074281-0B375E8A-2A95-446C-8BE3-F67A68EF8C0DQ39221674-E4F8752F-4D3E-4029-9CB8-D3BECAEC6698Q39326649-68271AF0-4C06-4306-8058-4C478821CFE2Q40462770-11D7EDC0-5788-4786-BC07-BD09A244A830Q41694346-F15C4970-BB04-47A4-9DFC-07790312D4F1Q43082545-7809F533-963F-426D-94FE-D4A6B617FED7Q47113667-85860BAF-4037-4367-9659-EE21CC3A1C4A
P2860
Resistance to BRAF inhibitors: unraveling mechanisms and future treatment options
description
2011 nî lūn-bûn
@nan
2011 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Resistance to BRAF inhibitors: unraveling mechanisms and future treatment options
@ast
Resistance to BRAF inhibitors: unraveling mechanisms and future treatment options
@en
Resistance to BRAF inhibitors: unraveling mechanisms and future treatment options
@nl
type
label
Resistance to BRAF inhibitors: unraveling mechanisms and future treatment options
@ast
Resistance to BRAF inhibitors: unraveling mechanisms and future treatment options
@en
Resistance to BRAF inhibitors: unraveling mechanisms and future treatment options
@nl
prefLabel
Resistance to BRAF inhibitors: unraveling mechanisms and future treatment options
@ast
Resistance to BRAF inhibitors: unraveling mechanisms and future treatment options
@en
Resistance to BRAF inhibitors: unraveling mechanisms and future treatment options
@nl
P2093
P2860
P3181
P1433
P1476
Resistance to BRAF inhibitors: unraveling mechanisms and future treatment options
@en
P2093
J. Villanueva
P2860
P304
P3181
P356
10.1158/0008-5472.CAN-11-1243
P407
P577
2011-12-01T00:00:00Z